Finance

Lists
Why is CBIO down 10,72%?
Dive Deeper
CBIO:NASDAQ
Crescent Biopharma Inc
12,91 $
-10,72%
(-1,55) 1D
12,91 $
0,00% (0,00)
After hours
Closed: 13 հոկ, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CBIO...
Open
14,46 $
High
14,67 $
Low
12,85 $
Mkt. cap
479,53 մլն
Avg. vol.
503,00 հզր
Volume
197,11 հզր
52-wk high
27,41 $
52-wk low
8,72 $
EPS
-7,41 $
Beta
1,27
Shares outstanding
37,14 մլն
No. of employees
69
Open
14,46 $
High
14,67 $
Low
12,85 $
Mkt. cap
479,53 մլն
Avg. vol.
503,00 հզր
Volume
197,11 հզր
52-wk high
27,41 $
52-wk low
8,72 $
EPS
-7,41 $
Beta
1,27
Shares outstanding
37,14 մլն
No. of employees
69
News stories
From web sources and news partners
About Crescent Biopharma Inc
CEO-
Employees69
Founded2024
HeadquartersՈւոլթեմ, Մասսաչուսեթս, Միացյալ Նահանգներ
Sector-
Websitecrescentbiopharma.com
Analyst ratings
Based on 4 analysts giving stock ratings to CBIO in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for CBIO in the last 3 months.
Highest
Current 12,91 $
36,00 $ (+178,85%)
Average
29,75 $ (+130,44%)
Lowest
27,00 $ (+109,14%)
Analyst
Recommendation
Action
Price target
Projected
Date
Stephen Willey
Stifel Nicolaus
Buy
Maintained
28,00 $
+116,9%
10/06/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Upgraded
36,00 $
+178,9%
10/06/2026
Charles Zhu
LifeSci Capital
Buy
Maintained
28,00 $
+116,9%
10/05/2026
Robert Driscoll
Wedbush
Buy
Maintained
27,00 $
+109,1%
09/14/2026
Unknown Analyst
Wedbush
Buy
Maintained
27,00 $
+109,1%
09/14/2026
Biren Amin
Piper Sandler
Buy
Maintained
35,00 $
+171,1%
06/23/2026
Bradley Canino
Guggenheim
Buy
Maintained
35,00 $
+171,1%
04/29/2026
Phil Nadeau
TD Cowen
Buy
Maintained
-
-
04/29/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
-
10,84 մլն
1,04 մլն
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
20,35 մլն
95,03 մլն
17,90 մլն
19,39 մլն
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5,54 մլն
7,31 մլն
7,86 մլն
8,74 մլն
Operating expense
25,88 մլն
102,34 մլն
25,77 մլն
28,13 մլն
Total operating expenses
25,88 մլն
102,34 մլն
25,77 մլն
28,13 մլն
Operating income
-25,88 մլն
-91,49 մլն
-24,73 մլն
-28,13 մլն
Other non operating income
-
-
-
-
EBT including unusual items
-24,61 մլն
-90,40 մլն
-23,28 մլն
-24,84 մլն
EBT excluding unusual items
-24,61 մլն
-90,40 մլն
-23,28 մլն
-26,61 մլն
Income tax expense
-
2,00 մլն
-
-
Effective tax rate
-
-2,21%
-
-
Other operating expenses
-
-
-
-
Net income
-24,61 մլն
-92,40 մլն
-23,28 մլն
-24,84 մլն
Net profit margin
-
-852,06%
-2 240,90%
-
Earnings per share
-1,37
-4,92
-0,70
-0,62
Interest and investment income
1,28 մլն
1,10 մլն
1,45 մլն
1,53 մլն
Interest expense
-
-
-
-
Net interest expenses
1,28 մլն
1,10 մլն
1,45 մլն
1,53 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
-25,86 մլն
-91,44 մլն
-24,66 մլն
-28,07 մլն
Gain or loss from assets sale
-
-
-
-1,77 մլն
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google Apps